Mast cell activation syndrome (MCAS) affects more than 15% of the U.S. population but evades most practitioners’ radar. Just five years ago, it wasn’t even on my radar, despite already having 20 years of experience as a clinician at that time. The more I dug (similar to leaky gut and post-COVID syndrome), the more I found my patients were suffering from this disorder.
Pam Ferguson, Dipl. ABT (NCCAOM), AOBTA & GSD-CI, LMT
Pamela Ellen Ferguson is semi-retired after years of teaching primarily CEU and advanced ABT courses in the U.S., Canada, Switzerland, Germany and Austria. She was AOMA’s dean emerita of ABT and a former board member of the AOBTA. For previous column articles, visit her online columnist page. She also welcomes comments via email: pamelacudot@gmail.com.